- Home
- QLGN vs ONCO Comparison
QLGN vs ONCO Comparison
Compare QLGN & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- ONCO
- Stock Information
- Founded
- QLGN 1996
- ONCO 2018
- Country
- QLGN United States
- ONCO United States
- Employees
- QLGN N/A
- ONCO N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- ONCO Health Care
- Exchange
- QLGN Nasdaq
- ONCO Nasdaq
- Market Cap
- QLGN 4.8M
- ONCO 4.7M
- IPO Year
- QLGN N/A
- ONCO 2022
- Fundamental
- Price
- QLGN $5.02
- ONCO $3.33
- Analyst Decision
- QLGN
- ONCO
- Analyst Count
- QLGN 0
- ONCO 0
- Target Price
- QLGN N/A
- ONCO N/A
- AVG Volume (30 Days)
- QLGN 4.8M
- ONCO 257.0K
- Earning Date
- QLGN 11-13-2025
- ONCO 08-14-2025
- Dividend Yield
- QLGN N/A
- ONCO N/A
- EPS Growth
- QLGN N/A
- ONCO N/A
- EPS
- QLGN N/A
- ONCO N/A
- Revenue
- QLGN N/A
- ONCO $1,326,959.00
- Revenue This Year
- QLGN N/A
- ONCO N/A
- Revenue Next Year
- QLGN N/A
- ONCO N/A
- P/E Ratio
- QLGN N/A
- ONCO N/A
- Revenue Growth
- QLGN N/A
- ONCO N/A
- 52 Week Low
- QLGN $1.61
- ONCO $2.45
- 52 Week High
- QLGN $10.45
- ONCO $552.50
- Technical
- Relative Strength Index (RSI)
- QLGN 61.57
- ONCO 55.12
- Support Level
- QLGN $4.91
- ONCO $3.02
- Resistance Level
- QLGN $6.16
- ONCO $3.24
- Average True Range (ATR)
- QLGN 1.00
- ONCO 0.32
- MACD
- QLGN 0.06
- ONCO 0.02
- Stochastic Oscillator
- QLGN 43.01
- ONCO 64.05
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.